Stockscreener 앱 받기
1.65
4.07%
-0.07
전일 마감가:
$1.72
열려 있는:
$2
하루 거래량:
30,776
Relative Volume:
0.71
시가총액:
$1.75M
수익:
-
순이익/손실:
$-40.36M
주가수익비율:
-0.0339
EPS:
-48.648
순현금흐름:
$-21.40M
1주 성능:
-2.37%
1개월 성능:
-49.07%
6개월 성능:
-82.72%
1년 성능:
-85.31%
1일 변동 폭
$1.65
$2.00
1주일 범위
$1.5785
$2.00
52주 변동 폭
$1.5785
$20.99
트랜스코드 테라 Stock (RNAZ) Company Profile
명칭
Transcode Therapeutics Inc
전화
857-301-6857
주소
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
1.65 | 1.79M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
트랜스코드 테라 주식(RNAZ)의 최신 뉴스
TransCode Therapeutics Share PriceRNAZ, RNS News, Articles, Quotes, & Charts (NASDAQ:RNAZ) - Proactive financial news
TransCode Therapeutics CFO Resigns, Interim Replacement Named - minichart.com.sg
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com
TransCode Therapeutics Announces CFO Resignation and Interim Appointment - TipRanks
Transcode Therapeutics (RNAZ) grants CFO 185,000 options with 10-year term - Stock Titan
CFO exit at TransCode Therapeutics (RNAZ) comes with severance tied to future funding - Stock Titan
TransCode Therapeutics Appoints Interim CFO Following Retirement of Tom Fitzgerald - citybuzz -
TransCode Therapeutics Appoints John Tattory As Interim CFO - TradingView
Transcode Therapeutics, Inc. Announces CFO Changes, Effective September 10, 2026 - marketscreener.com
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer - Yahoo Finance
An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Yield Spread - vinanet.vn
TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan
TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionExhaustion Gap - vinanet.vn
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65Sector Neutral Pair - vinanet.vn
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transcode Therapeutics Inc (RNAZ) Stock News Today - TradingKey
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
Why (RNAZ) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Major holder converts preferred shares at Transcode Therapeutics, Inc. (RNAZ) - stocktitan.net
Transcode Therapeutics (RNAZ) major holders disclose convertible preferred stake - Stock Titan
TransCode Therapeutics Updates Preferred Stock Governance Terms - The Globe and Mail
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
TransCode Therapeutics (RNAZ) Retreats 2.7% to $4.62, Approaching Key Support ZoneSynthetic Short - vinanet.vn
TransCode Therapeutics Q4 2024 Earnings: Wider-than-Expected Loss of -$150.64 Per Share Signals Ongoing Clinical-Stage Cash BurnFinancial Health Score - siam.in
RNAZ|Transcode Therapeutics Inc|Price:5.800|Chg%:-0.130 - TradingKey
Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake - Stock Titan
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TransCode Therapeutics (RNAZ) holder moves toward controlling stake via conversions - Stock Titan
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNAZ|Transcode Therapeutics Inc|Price:5.930|Chg%:-1.170 - TradingKey
Transcode Therapeutics Inc (RNAZ) Balance Sheet - TradingKey
TransCode Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAZ - TradingView
RNAZ|Transcode Therapeutics Inc|Price:3.995|Chg%:+0.035 - TradingKey
Transcode Therapeutics Inc (RNAZ) Cash Flow - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
ON: ON Semiconductor Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake - Stock Titan
TransCode Therapeutics (RNAZ) Proxy Filing Summary - Quartr
TransCode Therapeutics, Inc. (RNAZ) 8-K: Key Nasdaq Approvals and Stockholder Vote Results July 2026 - Minichart
TransCode Therapeutics Inc. (RNAZ) Q4 2024 Earnings: Deep Losses on No Revenue as Cash Burn Persists - dars.gov.et
TransCode Therapeutics Shareholders Approve Key Capital Measures - TipRanks
TransCode Therapeutics (RNAZ) AGM 2026 Summary - Quartr
RNAZ Q4 2024 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentFinancial Data - vinanet.vn
트랜스코드 테라 (RNAZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
자본화:
|
볼륨(24시간):